Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-620,401
Closed -$36.1M 4446
2026
Q1
$36.1M Buy
620,401
+458,787
+284% +$24.9M 0.05% 518
2025
Q4
$7.46M Sell
161,614
-535,229
-77% -$23.9M 0.01% 1544
2025
Q3
$25.1M Buy
+696,843
New +$23.1M 0.04% 478
2025
Q2
Sell
-245,317
Closed -$9.26M 2500
2025
Q1
$9.26M Sell
245,317
-5,738
-2% -$459K 0.02% 707
2024
Q4
$20.6M Sell
251,055
-108,741
-30% -$10.8M 0.05% 438
2024
Q3
$41.1M Buy
+359,796
New +$32.4M 0.1% 229
2024
Q1
Sell
-30,155
Closed -$1.89M 2519
2023
Q4
$1.89M Sell
30,155
-621,030
-95% -$32.3M ﹤0.01% 1227
2023
Q3
$33.2M Buy
651,185
+452,789
+228% +$22.3M 0.1% 271
2023
Q2
$9.91M Sell
198,396
-302,704
-60% -$14.3M 0.03% 587
2023
Q1
$18.8M Buy
501,100
+198,500
+66% +$8.42M 0.06% 368
2022
Q4
$14.5M Sell
302,600
-120,200
-28% -$4.72M 0.05% 429
2022
Q3
$10.1M Buy
+422,800
New +$10.7M 0.04% 500

Other funds holding PCVX

Steven Cohen's PCVX Position: Q2 2026 in Review

Steven Cohen sold out of Vaxcyte (PCVX) in Q2 2026, closing a stake of 620,401 shares — an estimated $36.1M sold.

Steven Cohen first reported a position in PCVX in Q3 2022 and held it in 12 quarters. The position peaked at $41.1M in Q3 2024. 330 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Steven Cohen reported no remaining Vaxcyte position as of Q2 2026 after selling out during the quarter.
  • Steven Cohen sold 620,401 Vaxcyte shares in Q2 2026, an estimated $36.1M.
  • Steven Cohen first reported a position in Vaxcyte in Q3 2022 and held it in 12 quarters.
  • Steven Cohen's Vaxcyte position peaked at $41.1M in Q3 2024.
  • 330 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.